The mRNA technology behind COVID vaccines is being aimed at cancer. Personalized shots encode a patient’s specific tumor mutations to train the immune system. In 2023 a melanoma vaccine advanced toward larger trials with promising early data.
Personalized design
Each shot is bespoke. Sequencing a tumor reveals its unique mutations. The vaccine encodes them.
Train the immune system
The aim is recognition. T cells learn to hunt cells bearing the mutations. Immunity is directed.
Combination therapy
Pairing helps. The vaccine is tested alongside immune-checkpoint drugs. Effects may add.
Early signals
Data encouraged. A melanoma trial hinted at reduced recurrence. Larger studies followed.
Manufacturing speed
Turnaround matters. A personalized vaccine must be made quickly. Logistics are demanding.
Broad ambition
Scope is wide. Other cancers are being targeted similarly. The field is racing.
The bottom line
Personalized mRNA cancer vaccines encode a patient’s tumor mutations to direct the immune system. A melanoma candidate advanced with promising data in 2023. Larger trials will test the approach.
